- Home
- ESPR
as of 12-15-2025 3:39pm EST
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | ANN ARBOR |
| Market Cap: | 898.5M | IPO Year: | 2013 |
| Target Price: | $6.86 | AVG Volume (30 days): | 6.5M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.69 - $4.13 | Next Earning Date: | 11-06-2025 |
| Revenue: | $303,802,000 | Revenue Growth: | 2.83% |
| Revenue Growth (this year): | 25.45% | Revenue Growth (next year): | -4.27% |
AI-Powered ESPR Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Esperion Therapeutics Inc. (ESPR)
General Counsel
Avg Cost/Share
$2.62
Shares
1,248
Total Value
$3,275.38
Owned After
392,422
SEC Form 4
General Counsel
Avg Cost/Share
$2.80
Shares
6,267
Total Value
$17,572.67
Owned After
392,422
SEC Form 4
President and CEO
Avg Cost/Share
$2.79
Shares
28,427
Total Value
$79,254.48
Owned After
1,518,831
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$2.81
Shares
7,046
Total Value
$19,785.17
Owned After
474,862
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Looker Benjamin | ESPR | General Counsel | Oct 17, 2025 | Sell | $2.62 | 1,248 | $3,275.38 | 392,422 | |
| Looker Benjamin | ESPR | General Counsel | Sep 17, 2025 | Sell | $2.80 | 6,267 | $17,572.67 | 392,422 | |
| Koenig Sheldon L. | ESPR | President and CEO | Sep 17, 2025 | Sell | $2.79 | 28,427 | $79,254.48 | 1,518,831 | |
| Halladay Benjamin | ESPR | Chief Financial Officer | Sep 17, 2025 | Sell | $2.81 | 7,046 | $19,785.17 | 474,862 |
Compare ESPR vs Leading Stocks
See how ESPR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ESPR Esperion Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.